Glucagon-Like Peptide 1
Novo Nordisk pens $2B deal for triple G agonist tied to 15% weight loss at 12 weeks
Novo Nordisk, UBT251, obesity treatment, triple agonist, weight loss, GLP-1, GIP, glucagon, The United Laboratories International Holdings Limited
GLP-1 Players Seek to Differentiate in Increasingly Crowded Weight Loss Space
GLP-1 drugs, weight loss market, differentiation, competition, obesity treatment
Novo’s Studies of GLP-1s for Addiction Limited to Ongoing Phase II
GLP-1, addiction treatment, semaglutide, clinical trials, Novo Nordisk
Novo Nordisk looks into starting GLP-1 drug trials for addiction
Glucagon-Like Peptide 1, Addictive Behavior
Ascletis Advances in Obesity Treatment with Promising Oral GLP-1 Data
Ascletis Pharma, oral GLP-1, obesity treatment, weight loss, ASC30, Chinese biotech, pharmaceutical innovation
Semaglutide Shows Promise in Reducing Alcohol Consumption, Small Study Reveals
semaglutide, Ozempic, Wegovy, alcohol use disorder, GLP-1 drugs, alcohol cravings, weight loss medication, addiction treatment
Axplora Invests €50M in GLP-1 Manufacturing Expansion at Mourenx, France
Axplora, GLP-1, manufacturing expansion, Mourenx, France, CDMO, API production, chromatography, diabetes, obesity, biologic therapies
Hims & Hers Super Bowl Ad Sparks Controversy Over Weight Loss Drug Marketing
Hims & Hers, Super Bowl ad, weight loss drugs, FDA scrutiny, compounded GLP-1 drugs, pharmaceutical advertising, telehealth, consumer safety
Eli Lilly’s Zepbound Surpasses $4.9 Billion in First Year Sales Despite Q4 Shortfall
Eli Lilly, Zepbound, obesity drug, Q4 2024 earnings, pharmaceutical revenue, GLP-1 medications, Mounjaro, 2025 guidance
GLP-1 Weight Loss Drugs Make Super Bowl Advertising Debut Amid Shifting Health Marketing Landscape
GLP-1, Super Bowl ads, Hims & Hers, weight loss drugs, pharmaceutical marketing, healthcare advertising, obesity epidemic